Jan 11, 2021 / 03:50PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome, everybody, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.
The next presenting company, we have is Agios. And speaking on behalf of the company, we have CEO, Jackie Fouse. Before I turn it over to Jackie, just wanted to highlight to the listeners on the webcast that you can submit a question by the ask-a-question feature in the portal, and I'm happy to ask those questions on your behalf. Jackie?
Jacqualyn A. Fouse - Agios Pharmaceuticals, Inc. - CEO & Director
Thanks, Anupam. Hi, everybody. Thank you for joining us for our Agios presentation at the conference today.
So back on December 21, we announced a 2-part change in our strategy, and it is something I'll cover with you today. We're very excited about where we're going at Agios and where we are with respect to leveraging the strengths that we've built up over our
Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
